The effect of continuous long-term ADT on reducing the visibility of castration-sensitive prostate cancer lesions on PSMA-PET has already been investigated; however, it is still uncertain if initiation of ADT could interfere with the staging results [17]. The gene discussed is FOLH1; the disease is prostate cancer.